(Q43227528)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

1 reference

1 reference

metastatic colon cancer

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Ramazan Yildiz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Suleyman Buyukberber

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Aytug Uner

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Deniz Yamac

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Ugur Coskun

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Ali Osman Kaya

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Banu Ozturk

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Emel Yaman

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

1 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

33-37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900802562996

10.3109/07357900802562996

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995229%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference